{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:13:20Z","timestamp":1782321200037,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T00:00:00Z","timestamp":1536192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM099742"],"award-info":[{"award-number":["R01GM099742"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Federal Drug Administration","award":["U01FD004320"],"award-info":[{"award-number":["U01FD004320"]}]},{"name":"Federal Drug Administration","award":["1U01FD005946"],"award-info":[{"award-number":["1U01FD005946"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s11095-018-2486-2","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T16:21:08Z","timestamp":1536250868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity"],"prefix":"10.1007","volume":"35","author":[{"given":"Dong","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obinna","family":"Obianom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-3610","authenticated-orcid":false,"given":"Yan","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,6]]},"reference":[{"issue":"7","key":"2486_CR1","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/dna.1997.16.871","volume":"16","author":"V Gorboulev","year":"1997","unstructured":"Gorboulev V, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16(7):871\u201381.","journal-title":"DNA Cell Biol"},{"issue":"1","key":"2486_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/mol.56.1.1","volume":"56","author":"D Grundemann","year":"1999","unstructured":"Grundemann D, et al. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999;56(1):1\u201310.","journal-title":"Mol Pharmacol"},{"issue":"5","key":"2486_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2133\/dmpk.20.379","volume":"20","author":"N Kimura","year":"2005","unstructured":"Kimura N, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20(5):379\u201386.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"2486_CR4","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.bcp.2013.07.008","volume":"86","author":"F Muller","year":"2013","unstructured":"Muller F, et al. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochem Pharmacol. 2013;86(6):808\u201315.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2486_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s15010-012-0308-8","volume":"41","author":"N Jung","year":"2013","unstructured":"Jung N, et al. Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients. Infection. 2013;41(2):379\u201385.","journal-title":"Infection"},{"issue":"4","key":"2486_CR6","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1476-5381.2009.00569.x","volume":"159","author":"H Burger","year":"2010","unstructured":"Burger H, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010;159(4):898\u2013908.","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2486_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1023\/B:PHAM.0000029286.45788.ad","volume":"21","author":"Y Urakami","year":"2004","unstructured":"Urakami Y, et al. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res. 2004;21(6):976\u201381.","journal-title":"Pharm Res"},{"issue":"4","key":"2486_CR8","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1124\/dmd.114.060673","volume":"43","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, et al. Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110. Drug Metab Dispos. 2015;43(4):485\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2486_CR9","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.V134866","volume":"13","author":"H Motohashi","year":"2002","unstructured":"Motohashi H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13(4):866\u201374.","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"2486_CR10","doi-asserted-by":"publisher","first-page":"7902","DOI":"10.1128\/MCB.23.21.7902-7908.2003","volume":"23","author":"JW Jonker","year":"2003","unstructured":"Jonker JW, et al. Deficiency in the organic cation transporters 1 and 2 (Oct1\/Oct2 [Slc22a1\/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol. 2003;23(21):7902\u20138.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"2486_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/clpt.2009.139","volume":"86","author":"KK Filipski","year":"2009","unstructured":"Filipski KK, et al. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86(4):396\u2013402.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2486_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-012-0638-y","volume":"16","author":"K Iwata","year":"2012","unstructured":"Iwata K, et al. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol. 2012;16(6):843\u201351.","journal-title":"Clin Exp Nephrol"},{"issue":"11","key":"2486_CR13","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.bcp.2010.08.019","volume":"80","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, et al. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol. 2010;80(11):1762\u20137.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2486_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.taap.2013.08.024","volume":"273","author":"Q Li","year":"2013","unstructured":"Li Q, et al. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol. 2013;273(1):100\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"2486_CR15","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/jpet.106.110346","volume":"319","author":"A Yonezawa","year":"2006","unstructured":"Yonezawa A, et al. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319(2):879\u201386.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2486_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.bcp.2007.03.004","volume":"74","author":"S Yokoo","year":"2007","unstructured":"Yokoo S, et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem Pharmacol. 2007;74(3):477\u201387.","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"2486_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/BF02911522","volume":"42","author":"T Minami","year":"1994","unstructured":"Minami T, et al. Accumulation of platinum in the intervertebral discs and vertebrae of ovarian tumor-bearing patients treated with cisplatin. Biol Trace Elem Res. 1994;42(3):253\u20137.","journal-title":"Biol Trace Elem Res"},{"issue":"2\u20133","key":"2486_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tox.2007.12.031","volume":"246","author":"EJ Wang","year":"2008","unstructured":"Wang EJ, et al. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology. 2008;246(2\u20133):91\u2013100.","journal-title":"Toxicology"},{"issue":"3","key":"2486_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","volume":"10","author":"T Minematsu","year":"2011","unstructured":"Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011;10(3):531\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"2486_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nbt.1623","volume":"28","author":"VS Vaidya","year":"2010","unstructured":"Vaidya VS, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28(5):478\u201385.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"2486_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","volume":"65","author":"NE Madias","year":"1978","unstructured":"Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med. 1978;65(2):307\u201314.","journal-title":"Am J Med"},{"issue":"12","key":"2486_CR22","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.bcp.2005.09.020","volume":"70","author":"A Yonezawa","year":"2005","unstructured":"Yonezawa A, et al. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol. 2005;70(12):1823\u201331.","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"2486_CR23","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1002\/1097-0142(19871201)60:11<2823::AID-CNCR2820601138>3.0.CO;2-C","volume":"60","author":"DT Sleijfer","year":"1987","unstructured":"Sleijfer DT, et al. The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer. 1987;60(11):2823\u20138.","journal-title":"Cancer"},{"issue":"11","key":"2486_CR24","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1248\/bpb.33.1867","volume":"33","author":"H Katsuda","year":"2010","unstructured":"Katsuda H, et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull. 2010;33(11):1867\u201371.","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"2486_CR25","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.fct.2012.03.077","volume":"50","author":"J Zhang","year":"2012","unstructured":"Zhang J, Zhou W. Ameliorative effects of SLC22A2 gene polymorphism 808 G\/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012;50(7):2289\u201393.","journal-title":"Food Chem Toxicol"},{"issue":"5","key":"2486_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/clpt.2013.145","volume":"94","author":"JA Sprowl","year":"2013","unstructured":"Sprowl JA, et al. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther. 2013;94(5):585\u201392.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2486_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00390477","volume":"114","author":"RT Dorr","year":"1988","unstructured":"Dorr RT, Soble MJ. Cimetidine enhances cisplatin toxicity in mice. J Cancer Res Clin Oncol. 1988;114(1):1\u20132.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2486_CR28","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1124\/jpet.111.184986","volume":"340","author":"S Ito","year":"2012","unstructured":"Ito S, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012;340(2):393\u2013403.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"2486_CR29","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1021\/jm301302s","volume":"56","author":"MB Wittwer","year":"2013","unstructured":"Wittwer MB, et al. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. J Med Chem. 2013;56(3):781\u201395.","journal-title":"J Med Chem"},{"issue":"8","key":"2486_CR30","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1681\/ASN.2006030205","volume":"17","author":"S Masuda","year":"2006","unstructured":"Masuda S, et al. Identification and functional characterization of a new human kidney-specific H+\/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17(8):2127\u201335.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2486_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/17460441.1.1.85","volume":"1","author":"RR Ruffolo","year":"2006","unstructured":"Ruffolo RR, Feuerstein GZ. Carvedilol case history: the discovery and development of the first beta-blocker for the treatment of congestive heart failure. Expert Opin Drug Discovery. 2006;1(1):85\u20139.","journal-title":"Expert Opin Drug Discovery"},{"issue":"5","key":"2486_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/00003088-199426050-00002","volume":"26","author":"T Morgan","year":"1994","unstructured":"Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet. 1994;26(5):335\u201346.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2486_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ardp.19933260907","volume":"326","author":"E Stahl","year":"1993","unstructured":"Stahl E, et al. Carvedilol stereopharmacokinetics in rats: affinities to blood constituents and tissues. Arch Pharm (Weinheim). 1993;326(9):529\u201333.","journal-title":"Arch Pharm (Weinheim)"},{"issue":"9","key":"2486_CR34","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1002\/jps.23595","volume":"102","author":"N Nakamichi","year":"2013","unstructured":"Nakamichi N, et al. Involvement of carnitine\/organic cation transporter OCTN1\/SLC22A4 in gastrointestinal absorption of metformin. J Pharm Sci. 2013;102(9):3407\u201317.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"2486_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0005-2736(00)00189-9","volume":"1466","author":"X Wu","year":"2000","unstructured":"Wu X, et al. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000;1466(1\u20132):315\u201327.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"2486_CR36","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1124\/dmd.112.044875","volume":"40","author":"JW Higgins","year":"2012","unstructured":"Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos. 2012;40(6):1170\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"2486_CR37","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1021\/mp200395f","volume":"8","author":"Q Li","year":"2011","unstructured":"Li Q, et al. Deficiency of multidrug and toxin extrusion 1 enhances renal accumulation of paraquat and deteriorates kidney injury in mice. Mol Pharm. 2011;8(6):2476\u201383.","journal-title":"Mol Pharm"},{"issue":"1","key":"2486_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cbi.2013.08.015","volume":"206","author":"MA Carvalho Rodrigues","year":"2013","unstructured":"Carvalho Rodrigues MA, et al. Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice. Chem Biol Interact. 2013;206(1):90\u20139.","journal-title":"Chem Biol Interact"},{"issue":"16\u201317","key":"2486_CR39","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/15287394.2012.696512","volume":"75","author":"MA Carvalho Rodrigues","year":"2012","unstructured":"Carvalho Rodrigues MA, et al. Carvedilol protects against apoptotic cell death induced by cisplatin in renal tubular epithelial cells. J Toxic Environ Health A. 2012;75(16\u201317):981\u201390.","journal-title":"J Toxic Environ Health A"},{"issue":"1\u20132","key":"2486_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cbi.2010.10.014","volume":"189","author":"MA Rodrigues","year":"2011","unstructured":"Rodrigues MA, et al. Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chem Biol Interact. 2011;189(1\u20132):45\u201351.","journal-title":"Chem Biol Interact"},{"issue":"Suppl 1","key":"2486_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1023\/A:1007735729121","volume":"11","author":"RR Ruffolo Jr","year":"1997","unstructured":"Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther. 1997;11(Suppl 1):247\u201356.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"11","key":"2486_CR42","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1111\/j.1463-1326.2009.01076.x","volume":"11","author":"I Bachmakov","year":"2009","unstructured":"Bachmakov I, et al. Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes Metab. 2009;11(11):1080\u20133.","journal-title":"Diabetes Obes Metab"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-018-2486-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2486-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2486-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T21:17:35Z","timestamp":1661980655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-018-2486-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,6]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["2486"],"URL":"https:\/\/doi.org\/10.1007\/s11095-018-2486-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,6]]},"assertion":[{"value":"14 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"204"}}